Author of

• 20039

  +

  Poster Display Session (ID 63)

  • Event: ELCC 2017
  • Type: Poster Display Session
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 5/07/2017, 12:30 - 13:00, Hall 1

  • 19916

    +

    160P - BAP1 in advanced sporadic malignant pleural mesothelioma (ID 304)

    12:30 - 12:30  |  Author(s): N. Sabri
    • Abstract

    Background:
    BAP1 mutation has been previously described in familial malignant pleural mesothelioma (MPM), however a little is known about its role in sporadic MPM.
    
    Methods:
    This is a prospective study including all eligible cases of MPM presenting to NCI, Cairo University, Egypt during the years 2013-2016. BAP1 analysis was done by PCR. Patients received first line chemotherapy (Pemetrexed/platinum). Primary objective was to evaluate the rate of BAP1 mutation in MPM, secondary objectives: To evaluate the correlation of BAP1 mutation and objective response rate (ORR), progression free survival (PFS) and overall survival (OS) in advanced MPM.
    
    Results:
    Among 120 cases, 38.5% showed positive BAP1 mutation.56.5% in the mutated group showed overall clinical benefit (CR+PR+SD) versus 46.2% in the wild group. (P = 0.34). One year PFS in the mutated group was 50.5% versus 38.5% in the wild group. (P = 0.31). One-year OS in the mutated group was 54.5% versus 47.6% in the wild group. (P = 0.67).
    
    Conclusions:
    BAP1 mutation is present in high frequency in a Caucasian population however it was not associated with clinical outcome after first line platinum based chemotherapy.
    
    Clinical trial identification:
    
    
    Legal entity responsible for the study:
    National Cancer Institute and Faculty of Pharmacy, Cairo University, Egypt
    
    Funding:
    National Cancer Institute and Faculty of Pharmacy, Cairo University, Egypt
    
    Disclosure:
    All authors have declared no conflicts of interest.